Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Mir Lim

4PUBLICATIONS

17CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPaediatrics not elsewhere classified

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Sep 29, 2023

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.

Mir Lim, Maishara Muquith, Bernadette Miramontes

|Jul 24, 2023

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.

Stephanie L Alden, Mir Lim, Chester Kao

|Jan 12, 2023

Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Mir Lim, Patrick T Lynch, Xiaochen Bai

|Aug 05, 2020

Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.

Mir Lim, David S Shulman, Holly Roberts

Pageof 1

Frequent Collaborators

2 joint publications

David Hsiehchen

1 joint publications

Steven G DuBois

1 joint publications

Patrick T Lynch

1 joint publications

David Hsiehchen

1 joint publications

Stephanie L Alden

1 joint publications

Chester Kao

1 joint publications

Daniel Shu

1 joint publications

Amit G Singal

1 joint publications

Anne Noonan

1 joint publications

Paige Griffith

Frequent Collaborators

2 joint publications

David Hsiehchen

1 joint publications

Steven G DuBois

1 joint publications

Patrick T Lynch

1 joint publications

David Hsiehchen

Top Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on : Sep 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos

Top Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on : Sep 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos